{"filing":{"accession_number":"0001193125-26-346857","cik":"0001604464","ticker":"ATRA","company_name":"Atara Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"atra-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526346857/atra-20260812.htm"},"events":[{"id":27200,"run_id":24773,"accession_number":"0001193125-26-346857","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Atara Biotherapeutics disclosed second quarter 2026 financial results on August 12, 2026, including revenue of $0.6 million, net loss of $4.8 million (or $0.32 loss per share), and cash position of $9.9 million. The press release titled \"Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress\" is furnished as Exhibit 99.1, with detailed condensed consolidated balance sheets and statements of operations. This is a standard quarterly earnings release disclosing material financial results and cash runway guidance into mid-2027.","company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28623,"accession_number":"0001193125-26-346857","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Atara Biotherapeutics disclosed second quarter 2026 financial results on August 12, 2026, including revenue of $0.6 million, net loss of $4.8 million (or $0.32 loss per share), and cash position of $9.9 million. The press release titled \"Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress\" is furnished as Exhibit 99.1, with detailed condensed consolidated balance sheets and statements of operations. This is a standard quarterly earnings release disclosing material financial results and cash runway guidance into mid-2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:15:18.225096+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28623,"accession_number":"0001193125-26-346857","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Atara Biotherapeutics disclosed second quarter 2026 financial results on August 12, 2026, including revenue of $0.6 million, net loss of $4.8 million (or $0.32 loss per share), and cash position of $9.9 million. The press release titled \"Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress\" is furnished as Exhibit 99.1, with detailed condensed consolidated balance sheets and statements of operations. This is a standard quarterly earnings release disclosing material financial results and cash runway guidance into mid-2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:15:18.225096+00:00","company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","filing_date":"2026-08-12"}]}